Salarius Pharmaceuticals granted additional extension to regain Nasdaq compliance

2 days ago 2

Salarius Pharmaceuticals (NASDAQ:SLRX) on Monday said it has received notification from Nasdaq of an additional extension to regain compliance with listing rules by late July 2025.
As previously disclosed, Salarius must also regain compliance with Nasdaq's minimum bid price requirement by

Recommended For You